AllDocs -> cancers

Pancreatic Cancer Risk and Nutrition-Related Methyl- Group Availability Indicators in Male Smokers Rachael Z. Stolzenberg-Solomon, Demetrius Albanes, F. Javier Nieto, Terryl J. Hartman, Joseph A. Tangrea, Matti Rautalahti, Jacob Sehlub, Jarmo Virtamo, Philip R. Taylor Background: Few risk factors for pan- creatic cancer have been identified, with age and cigarette smoking being the most consistent. The protective ef- fect associated with consumption of fruits and vegetables—the major di- etary sources of folate—is suggestive of a role for factors influencing cellular methylation reactions; however, to our knowledge, no study has investigated this relationship. Whether biochemical indicators of methyl-group availability are associated with exocrine pancreatic cancer risk was the focus of ...

H:\Pharm-prov\UPDATE\UpdateImplementation\GI protocols_contact revised\GIPGEM_nov2003.docGIPGEM LAST REVISED: 1 Dec 2000 Page 1 of 3 BCCA Protocol Summary for Palliative Chemotherapy for Pancreatic Adenocarcinoma Cancer Using Gemcitabine Protocol Code: GIPGEM Tumour Group: Gastrointestinal Contact Physician: GI Systemic Therapy ELIGIBILITY: • Metastatic or unresectable pancreatic adenocarcinoma • ECOG 0-2 • Class II form must be completed for first 6 cycles. For further cycles, an “Individual use of Benefit Drug List Medication for an Undesignated Indication” form must be completed and approved. TESTS: Baseline: CBC, diff and platelets; creatinine, bilirubin, appropriate tumour markers and imaging study Before each treatment: CBC, diff and platelets If clinically indicated: bilirubin, creatinine After cycle 1, then every ...

Endowing Human Pancreatic Ribonuclease with Toxicity for Cancer Cells* Received for publication, July 16, 2001 Published, JBC Papers in Press, September 12, 2001, DOI 10.1074/jbc.M106636200 Peter A. Leland‡§, Kristine E. Staniszewski‡ ¶ , Byung-Moon Kim‡ , and Ronald T. Raines‡**‡‡ From the Departments of ‡ Biochemistry and ** Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706 Onconase ® is an amphibian protein that is now in Phase III clinical trials as a cancer chemotherapeutic. Human pancreatic ribonuclease (RNase 1) is homolo- gous to Onconase ® but is not cytotoxic. Here, ERDD RNase 1, which is the L86E/N88R/G89D/R91D variant of RNase 1, is shown to have conformational stability and ribonucleolytic activity similar to that of the wild-type enzyme but >10 ...

Summer, 2002 GWCCS Cancer Support Group & Internet Resource Guide Page 1 www.gwccs.org Greater Washington Coalition for Cancer Survivors (202) 364-6422 Pancreatic , Kidney & Liver Cancer Resources Organization/Phone Logo Web Site (URL) American Foundation for Urologic Disease (410) 468-1800 http://www.afud.org/ CancerAnswers (888) 226-8287 Http:www.canceranswers.com The Cancer Group Institute (305) 651-5070 Http:www.cancergroup.com Cancer Information and Support International Http:www. cancer -info.com/pancreas Ronald Hirshberg Foundation (310) 472-6310 http:www. pancreatic .org Johns Hopkins Medical Institutions (410) 955-5718 Http:www.path.jhu.edu/pancreas Kidney ...

research for a cure laboratory without walls National Foundation for Cancer Research Cancer FAQs about Pancreatic cancer Frequently Asked Questions about common cancers. Page 2 About Pancreatic Cancer The pancreas is located behind the stomach, extending horizontally across the middle of the abdomen. Its shape is often described as a long fish, because it is wide at one end (commonly referred to as the “head” of the pancreas) and narrow at the other (the “tail”). Overall, it is about six inches long and two inches wide. The pancreas is very complex, functioning as two separate glands ( exocrine and endocrine ) inside the same organ.The vast majority of pancreatic cells function as exocrine glands and ducts.The exocrine glands make pancreatic juice, which contains enzymes that break down fats, proteins ...

pancreatic cancer Pancreatic Cancer January 24, 2003 9:00 ? 10:00 AM Dr. Smoot Notes: Gemma Rolle He will try to keep his questions more clinical while Dr. Green will focus on the pathology. He has turned questions into Dr. Kassim already. The information that he used for the presentation will come from the pancreatitis section under pancreatic neoplasias that has a better explanation as opposed to pancreatic cancers section. Types of Pancreatic Cancer Pancreatic Ductal Adenocarcinoma ? main cancer we see with pancreas. Epidemiological aspect - it affects minorities more. I think a lot of it is nutritional because of the processed foods in this country and the minorities are a bigger intake of the processed foods. This is basically the bottom line in cancer risks, although there is always a genetic predisposition. ...

Tumori, 90: 192-195, 2004 Correspondence to: Ozkan Kanat, MD, Uludag University Faculty of Medicine Department of Medical Oncology, Gorukle 16059, Bursa, Turkey. Tel +90-224-4428400; fax +90-224-4428049; e-mail ozkanat@uludag.edu.tr Received July 7, 2003; accepted September 8, 2003. TREATMENT OF METASTATIC PANCREATIC CANCER WITH A COMBINATION OF GEMCITABINE AND 5-FLUOROURACIL: A SINGLE CENTER PHASE II STUDY Ozkan Kanat, Turkkan Evrensel, Ender Kurt, Mutlu Demiray, Guzin Gonullu, Murat Arslan, and Osman Manavoglu Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, Turkey Key words: chemotherapy, gemcitabine, 5-fluorouracil, pancreatic cancer . Aim : To determine the activity and toxicity of a combination of weekly gemcitabine and 5-fluorouracil bolus intravenously in patients with metastatic pancreatic cancer . Patients ...

182 Cryptosporidiosis of the biliary tract mimicking pancreatic cancer in an AIDS patient Criptosporidiose do trato biliar simulando câncer do pâncreas em paciente com AIDS Lenice do Rosário de Souza 1 , Maria Aparecida M. Rodrigues 1 , José Morceli 1 Raphael Kemp and Rinaldo Poncio Mendes 1 ABSTRACT Diarrhea caused by Cryptosporidium sp is frequent in patients with AIDS, but involvement of other organs of the digestive tract is uncommon. We report a case of Cryptosporidium -associated obstruction of the biliary tract mimicking cancer of the head of the pancreas in a 43-year-old woman with AIDS. Key-words: Cryptosporidiosis. AIDS. Biliary tract. Pancreatitis. RESUMO A diarréia causada pelo Cryptosporidium sp é muito freqüente em pacientes com aids, mas o envolvimento de outros ...

14. Cooper, M. K., Porter, J. A., Young, K. E. & Beachy, P. A. Plant-derived and synthetic teratogens inhibit the ability of target tissues to respond to Sonic hedgehog signaling. Science 280, 1603–1607 (1998). 15. Berman, D. M. et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297, 1559–1561 (2002). 16. Ericson, J., Morton, S., Kawakami, A., Roelink, H. & Jessell, T. M. Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identity. Cell 87, 661–673 (1996). 17. Wang, L. C. et al. Conditional disruption of hedgehog signaling pathway defines its critical role in hair development and regeneration. J. Invest. Dermatol. 114, 901–908 (2000). 18. Fuse, N. et al. Sonic hedgehog protein signals not as a hydrolytic enzyme but as an apparent ligand for patched. Proc. Natl Acad. Sci. USA 96, 10992–10999 (1999). 19. Goodrich, L. V., Milenkovic, L., ...

Bax-Induction Gene Therapy of Pancreatic Cancer Elissa C. Pirocanac, B.S.,* Rounak Nassirpour, M.S.,* Meng Yang, M.D., Ph.D.,* , † Jinwei Wang, M.D.,† Stephanie R. Nardin, B.S.,‡ Jian Gu, M.D.,‡ Bingliang Fang, M.D.,‡ A. R. Moossa, M.D.,* Robert M. Hoffman, Ph.D.,* , † and Michael Bouvet, M.D.* * Department of Surgery, University of California at San Diego, San Diego, California 92161; † AntiCancer, Inc., San Diego, California 92111; and ‡ Department of Cardiovascular and Thoracic Surgery, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 Submitted for publication January 22, 2002; published online July 19, 2002 Background. Bax is a strong pro-apoptotic gene that induces programmed cell death when ex- pressed. Human telomerase reverse transcriptase (hTERT) is the catalytic subunit for telomerase, an enzyme found to be ...

This issue is dedicated to Healthy Diet issues Editor: Zviad Kirtava; Deputy Editor: Kakha Paposhvili, Information support: Maka Kobaladze, Helen Phagava; Design: David Meskhishvili National Information Learning Centre (NILC) , Tbilisi, Georgia, 2002 NILC should be mentioned in case of reprints or references of the provided materials! Internet Medical Digest #5-6 (83-84) 01.05.2002 Fatty diet ups pancreatic cancer risk in smokers NEW YORK (Reuters Health) - Male smo kers who consume diets rich in saturated fat may be at increased risk of pancreatic cancer , researchers report. Their study findings suggest that dietary changes can help to lower the risk of pancreatic cancer , a disease in which fewer than 5% of patients live for 5 years after diagnosis. Until the tumor grows large, there are no symptoms, and the cancer usually ...

Patient Information Sheet Page 1 of 2 Version 3 - December 1999 (WPH - 20.7.01) Cancer Research Centre Weston Park Hospital Whitham Road Sheffield S10 2SJ U.K. ESPAC-3 –Additional Treatment in Operable Pancreatic Cancer PATIENT INFORMATION (Please read carefully) You have been invited to take part in a research study. Before you decide whether to participate it is important that you understand why the research is being done and what it will involve. Please take time to read the following information carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is anything that is not clear or if you would like more information. Take time to decide whether or not you wish to take part. This study has been designed to find out whether giving additional treatment after operation can help patients with your condition. What is the purpose ...

Patient Consent Form Version 3 – December 1999 ESPAC-3 Additional Treatment in Operable Pancreatic Cancer PATIENT CONSENT FORM (please read carefully) Name of Researcher:__ Please initial 1 . I confirm that I have read and understand the information sheet dated (version_) for the above study and have had an opportunity to ask questions. 2. I understand that my participation in this study is voluntary and that I am free to withdraw at any time without giving a reason, without my medical care or legal rights being affected. 3. I understand that sections of my medical notes may be looked at by responsible individuals involved in this research or from regulatory authorities where it is relevant to my taking part in research. I give permission for these individuals to have access to my records. 4. I agree to take part in the above study. __ __ ...

ANTI-ANGIOGENIC GENE THERAPY FOR PANCREATIC CANCER USING SOLUBLE VEGF RECEPTOR M. Sunamura, T. Hoshida, D. G. Duda, F. Motoi, K. Takeda, S. Matsuno Department of Surgery, Tohoku University School of Medicine, Sendai, Japan The growth of a tumor and its ability to metastasize is angiogenesis-dependent. Angiogenesis is one of the crucial steps in tumor's transition from a small, harmless cluster of mutated cells to a large, malignant growth, capable of spreading to other organs throughout the body. The purpose of this study is to clarify the efficacy of anti-angiogenesis gene therapy using soluble VEGF receptor (flt1) for pancreatic cancer which is recognized as hypovascular neoplasms. We measured the levels of VEGF protein in the conditioned media of ten human pancreatic cancer cell lines by ELISA and compared them to that of human umbilical vein endothelial cells. The expression of VEGF mRNA ...

CANCER Antineoplastics + TRAIL: synergistic antitumour activity 12 Capecitabine in pancreatic cancer 18 Imatinib mesylate : cytogenetic responses in CML 17 Imatinib mesylate : positive EU opinion for new indication 22 Imatinib mesylate therapy reviewed 3 Melphalan ± radiotherapy in multiple myeloma 18 p53 gene therapy : clinical success still a possibility 4 Satraplatin : limited activity in cervical cancer 12 TRAIL + antineoplastics: synergistic antitumour activity 12 Breast cancer risk: first consensus guidelines presented 2 CARDIO/VASCULAR Abciximab : effect of GP IIb/IIIa receptor polymorphism 20 Alteplase : study supports use in community hospitals 15 Alteplase in ischaemic stroke 18 Bemiparin sodium approved in 6 EU countries 22 ß -Blocker use improved with preprinted order forms 7 ...

NICE Technology Appraisal 25 Gemcitabine for pancreatic cancer Product Clinical condition Indicated for: Not indicated in: Impact of use on NHS Audit data to be collected NICE review date Gemcitabine Pancreatic cancer Patients with advanced or metastatic adenocarcinoma of the pancreas with Karnofsky performance score of 50 or more as first line chemotherapy Patients suitable for potentially curable surgery Patients with Karnofsky score less than 50 Insufficient evidence on use as second-line treatment of pancreatic adenocarcinoma Estimated 600-840 patients a year may be suitable Estimated total additional costs £816,000 - £3m per year Record management plans for each ...

Fas and Fas-ligand expression in human pancreatic cancer . Kornmann M, Ishiwata T, Kleeff J, Beger HG, Korc M. Department of Medicine, University of California, Irvine 92697, USA. OBJECTIVE: To investigate Fas and FasL expression in pancreatic tissues and cultured pancreatic cancer cell lines, and to assess the ability of anti-Fas antibodies to induce apoptosis. SUMMARY BACKGROUND DATA: Activation of the Fas receptor by Fas-ligand (FasL) results in apoptosis, and dysregulation of this pathway may contribute to abnormal cell proliferation. METHODS: Northern blotting and immunohistochemistry were used to compare Fas and FasL expression in normal and cancerous tissues. DNA 3'-OH end labeling was used to detect apoptotic cells. The effects of Fas activation on cell growth and signaling pathways were investigated in culture. RESULTS: Pancreatic cancers exhibited increased Fas RNA levels, whereas ...